Mitral valve regurgitation, the leakage of blood back to the left atrium during systole, is a significant cause of morbidity and mortality. The current treatment options for symptomatic mitral regurgitation are mitral valve replacement and mitral valve repair. However, the operative mortality for both of these treatments remains substantial[1]. Furthermore, these treatments are often not referred for elderly patients with comorbidities. Thus, there is a pressing need for less invasive, non-surgical treatments of mitral regurgitation.

This content is only available via PDF.
You do not currently have access to this content.